MyFinsight
Home
About
Contact
dnli: the balance sheet
Income Statement
|
Cash Flow
|
Balance Sheet
For the quarter ending 2025-09-30, DNLI has $1,055,621K in assets.
Balance Sheets Overview
00
No enough data to generate the overview
Subscribe for Financial Insights
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Quarterly
123
Balance Sheets
2025-09-30
2025-06-30
Total assets
1,055,621
1,166,241
Total stockholders' equity
926,197
1,027,053
Total liabilities and stockholders equity
1,055,621
1,166,241
Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Page 1
Buy me a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Prepaid expenses and
other current assets
$34,394K
Short-term marketable
securities
$757,241K
Cash and cash
equivalents
$90,963K
Other non-current
assets
$25,106K
Operating lease
right-of-use asset
$20,035K
Finance lease
right-of-use asset
$49,447K
Property and equipment,
net
$53,732K
Long-term marketable
securities
$24,703K
Total current assets
$882,598K
Total assets
$1,055,621K
Total liabilities and
stockholders equity
$1,055,621K
Total stockholders'
equity
$926,197K
Total liabilities
$129,424K
Accumulated deficit
-$1,922,975K
Accumulated other
comprehensive income
$1,101K
Additional paid-in capital
$2,846,278K
Deferred research
funding and development...
$4,038K
Finance lease
liability, less current...
$5,554K
Operating lease
liability, less current...
$29,686K
Total current
liabilities
$90,146K
Common stock, 0.01 par
value 400,000,000...
$1,793K
Other accrued costs
and current...
$4,942K
Deferred research and
development funding...
$22,580K
Operating lease
liability, current
$9,164K
Accrued manufacturing
costs
$5,002K
Accrued clinical and
other research and...
$23,355K
Accrued compensation
$18,358K
Accounts payable
$6,745K
Buy me a coffee
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)